Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
EBioMedicine
; 55: 102779, 2020 May.
Article
in En
| MEDLINE
| ID: mdl-32408111
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oxazines
/
Piperazines
/
Pyridones
/
RNA, Viral
/
HIV Infections
/
HIV-1
/
Lamivudine
/
Anti-HIV Agents
/
Heterocyclic Compounds, 3-Ring
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
EBioMedicine
Year:
2020
Document type:
Article
Affiliation country:
Spain
Country of publication:
Netherlands